在转移性乳腺癌患者中准雄激素受体
Lorenzo Guidi1,2,3, Dario Trapani1,2, Giuseppe Curigliano1,2
1Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS.
Current opinion in oncology
|October 1, 2025
概括
抗雄激素疗法在转移性乳腺癌中表现出有限的疗效,尽管针对的是雄激素受体 (AR) 阳性瘤. 未来的战略涉及组合疗法和新药,以克服耐药性并改善结果.
科学领域:
- 在瘤学瘤学.
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 转移性乳腺癌 (MBC) 包括激素受体阳性和三阴性亚型.
- 雄激素受体 (AR) 表达越来越被认为是特定MBC亚型的治疗标.
- 目前对AR阳性MBC的治疗模式正在发展.
研究的目的:
- 对AR阳性MBC的抗雄激素疗法的当前临床证据进行审查.
- 探索未来的前景,包括新的药物和组合策略.
- 讨论AR向治疗的耐药性和生物标志物发展机制.
主要方法:
- 临床试验和临床前研究的系统审查.
- 对激素受体阳性和三阴性MBC中AR向药物的数据分析.
- 对组合疗法和下一代AR抑制剂的评估.
主要成果:
- 抗雄激素疗法在AR阳性MBC中表现出适度的活性,有效性可变.
- 组合疗法 (例如,使用CDK4/6或PI3K/AKT/mTOR抑制剂) 在克服抗药性方面表现有前途.
- 新一代药物 (PROTACs,非LBD抑制剂,表观遗传调节剂) 提供了新的AR向方法.
结论:
- 目前抗雄激素疗法在MBC中的临床疗效仍然有限,需要改进患者选择.
- 验证的预测生物标志物对于优化患者选择和治疗反应至关重要.
- 组合疗法和下一代药物是克服耐药性和改善AR驱动乳腺癌的结果的关键.
相关概念视频
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
02:38Mitogens and the Cell Cycle
7.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K